SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending ahead of its earnings release as investors weigh the company's massive cash position and improved profitability against frustrations over the lack of a clear acquisition strategy and the company's decision to bypass a traditional conference call. While some shareholders are pushing for a 'No' vote on the CEO's compensation package, the community remains deeply divided between those betting on a long-term 'deep value' transformation and others who feel the stock has become a stagnant play dominated by algorithmic trading and short interest.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is currently trending as traders debate whether it is a high-potential turnaround play leveraging AI-integrated mortgage innovation or a fundamentally challenged firm vulnerable to macroeconomic pressures. The community remains deeply divided, with bulls pointing to aggressive growth and leadership updates while bears focus on geopolitical risks, interest rate pressures, and potential downside price discovery.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is experiencing extreme volatility and a surge in investor interest, driven by its indirect exposure to high-profile AI companies like Anthropic, OpenAI, and SpaceX. Community discourse is highly polarized, with many retail traders excited by the momentum and the scarcity of available shares due to lock-up periods, while skeptics warn of massive overvaluation relative to the underlying net asset value and potential for a significant correction.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors digest the unexpected pre-release of quarterly earnings alongside a doubled revenue outlook and the acquisition of World View, sparking intense debate over whether the company's aggressive growth strategy justifies its valuation. The community is focused on the upcoming conference call, with many traders looking for further clarity on profitability and potential partnerships to break the stock out of its recent range-bound trading pattern.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing extreme volatility and intense community debate following a reported legislative draft that would ban interest-bearing stablecoin yields, sparking fears that its core reserve-income business model is under threat. While some traders are aggressively shorting the stock on concerns of a permanent loss of competitive edge, others are dismissing the sell-off as an overreaction to "fake news" or algorithmic FUD, maintaining a bullish outlook on the stock's role in the future of digital payments.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative meme coin on the Solana network, igniting polarized community debates between investors betting on explosive, rapid gains and skeptics warning of a classic pump-and-dump scheme. The conversation is dominated by social media promotion and FOMO, with participants actively tracking its liquidity, holder concentration, and potential for volatility.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently facing significant investor skepticism and volatility as the community reacts to the implementation of a 1-for-12 reverse stock split. Investors are actively debating the company's long-term viability, citing concerns over subscriber retention, a lack of transparent management communication, and fears of further dilution despite the firm's consolidated sports-streaming strategy.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant volatility as investors weigh the potential impact of Costco's new private-label energy drink against the brand's continued growth, with many community members dismissing the competition as a short-term overreaction. Despite concerns about the stock's recent decline and the broader market environment, many long-term holders are actively viewing these price levels as a favorable entry point, emphasizing the strength of the Celsius and Alani Nu brands.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing extreme volatility and a sharp sell-off, driven by investors liquidating precious metals to cover losses in broader markets and concerns over rising Treasury yields. The community is deeply divided, with many debating if this is a capitulation-style buying opportunity or a signal that gold's status as a 'safe-haven' asset has been permanently compromised by institutional selling.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly is seeing renewed investor interest driven by its expanding role in U.S. defense, particularly through recent contracts to provide FPV drones and training to Air Force Special Operations. The community is actively debating the company's growth trajectory and competitive standing against peers like ONDS and RCAT, with many closely tracking potential military contract news and the firm's overall manufacturing scale-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.read more...

<ul class="summary-bullets"><li>The company announced a 1-for-25 reverse stock split.</li><li>The split takes effect Thursday, with split-adjusted trading Friday, reducing outstanding shares to about 1.1 million from 27.8 million.</li><li>The move comes amid continued progress on AD04, with Phase 3 planning completed.</li></ul>Shares of Adial Pharmaceuticals Inc.&nbsp;cratered over 20% in after-hours trading on Tuesday after the company announced a 1-for-25 reverse stock split to restore compliance with Nasdaq’s minimum bid price requirement.<h2 class="st-heading-2">ADIL Reverse Stock Split&nbsp;</h2>Adial said the reverse split will take effect Thursday, with the stock set to begin trading on a split-adjusted basis on Friday. This will reduce outstanding common shares to nearly 1.1 million from about 27.8 million, while shareholder ownership percentages will remain unchanged, apart from the treatment of fractional shares. The company added that proportional adjustments will be made to outstanding equity awards and warrants, including exercise prices.Adial said the reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule, a requirement for maintaining its listing.<h2 class="st-heading-2">AD04 Development In Focus</h2>The reverse split comes as Adial continues to advance AD04, its genetically targeted serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder, with a focus on heavy drinking patients and select genotypes.The company has advanced Phase 3 trial design and planning, drawing on analyses of historical clinical data that identified genotype-defined subgroups more likely to benefit from the therapy.&nbsp;On the regulatory front, Adial completed its End-of-Phase-2 discussions with the U.S. Food and Drug Administration (FDA), saying the agency provided input on the Phase 3 adaptive trial design and the broader clinical program. The company said the discussions covered key elements such as patient population, endpoints, dosing, and confirmation of biomarker-positive and biomarker-negative groups, including a focus on the AG+ genotype, and were later formalized through final FDA meeting minutes.Adial has also worked to strengthen intellectual property protection for AD04, saying an international patent application covering the program has been published and, if granted, is expected to protect its core assets through at least 2045.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/adil_ss_png_001d17e3e8.webp" alt="adil ss.png" width="975" height="148"><figcaption>ADIL sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user said the market reaction appeared overly short-term focused, adding that near-term share price moves mattered less to them, as they viewed Adial as a “long-term story” and said the company’s underlying clinical progress has been moving well.<stembedurl>https://stocktwits.com/Prazzclatt/message/643712705</stembedurl>Another user said, “more dilution will follow after min price bid met. It will be voted on at end of the month. This will likely be below $1 again by March.”<stembedurl>https://stocktwits.com/StayPresent/message/643885507</stembedurl><a href="https://stocktwits.com/symbol/ADIL">ADIL’s stock</a> has declined 75% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Equity

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADIL News

ADILAdial Pharmaceuticals Inc